Accenture plc (ACN - Free Report) reported third-quarter fiscal 2018 results, (ended Mar 31, 2018) adjusted earnings per share of $1.79, which surpassed the Zacks Consensus Estimate of $1.71. Earnings increased 17.8% on a year-over-year basis.
How Was the Estimate Revision Trend?
Investors should note that the Zacks Consensus Estimate for third-quarter fiscal 2018 earnings remained unchanged over the last 30 days.
The company has an impressive earnings history having outperformed the Zacks Consensus Estimate in all of the last four quarters with an average positive surprise of 3.8%.
Revenues Higher Than Expected
Accenture recorded revenues (before reimbursements) of $10.31 billion which beat the Zacks Consensus Estimate of $10.02 billion. Revenues compared favorably with the year-ago figure of $8.9 billion.
Accenture PLC Price
Key Stas to Note: The company witnessed year-over-year growth in revenue, primarily aided by an increase in Consulting and Outsourcing revenues. For 4Q18, Accenture expects revenue to be in the range of $9.80 billion to $10.05 billion.
Zacks Rank: Currently, Accenture has a Zacks Rank #4 (Sell) but that could change following the company’s earnings report which was just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Check back later for our full write up on this Accenture earnings report later!
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>